Pirana is a flexible and extendible modeling workbench with an intuitive graphical user interface for facilitating pharmacometric workflows for NONMEM, PsN, Xpose/R, and more. Pirana’s research tools facilitate the iterative processes used to create Pop PK/PD models, resulting in better organization and more efficient analysis of results.
It is a multi-functional, cloud-based, 21 CFR Part 11 compliant platform for clinical pharmacology, pharmacometrics and clinical operations professionals.
Maximize your understanding of your anti-cancer drug’s safety and efficacy profile to achieve regulatory and commercial success with Certara’s strategic and technology-enabled services across the entire drug development continuum – from pre-clinical first-in-human studies to regulatory submissions, health economics/outcomes research and market access value communication.
Certara® the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, announced today that it has appointed Dr. William F. Feehery as its new Chief Executive Officer (CEO) and a member of the Certara Board of Directors, effective June 3, 2019.
This webinar explained how advanced analytics using real-world data can mitigate challenges in Alzheimer’s disease drug approval, reimbursement and utilization.
This webinar explored a new version of a 21 CFR Part 11 compliant data repository that significantly improves the clinical pharmacology workflow.
This blog reviews trends for using health economics and outcomes research and real-world evidence to evaluate the value of medicines and health technologies.
This webinar discussed how Certara’s PBPK platform, the Simcyp®️ Simulator, was used to assess the risk-benefit profile for ethinylestradiol, the estrogen component of most combined oral contraceptives.
